1Kasof G M, Comes B C. Livin, a novel inhibitor of apoptosis protein family member[J]. J Biol Chem, 2001,276(2): 3238-3246.
2Choi K S, Lee T H, Jung M H. Ribozyme-mediated cleavage of the human survivin mRNA and inhibition of antiapoptotic function of survivin in MGF-7 cells [J]. Cancer Gene Ther, 2003,10(2): 87-95.
3Vocaturo A,Novelli F,Benevolo M,et al.Chromogenic in situ hybridization to detect HER-2/neu gene amplification in histological and ThinPrep?-Processed breast cancer fine-needle aspirates: a sensitive and practical method in the trastuzumab era [J]. The Oncotogist, 2006,11:8-878.
4Bhargava R, Lal P, Chen B. Chromogenie in situ hybridization for the detection of HER-2/neu gene amplification in breast cancer with an emphasis on tumors with borderline anti low-level amplification: does it measure up to fluorescence in situ hybridization [J] .Am J Clin Pathol, 2005. 123:237-243.
5Isola J, Tanner M, Forsyth A, et al. Interlaboratory comparison of HER- 2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization[J]. Clin Cancer Res, 2004, 10:4793-4798.
6Arnould L, Denoux Y, MacGrogan G, et al. Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer[J]. Br J Cancer 2003.88:1587-1591.
7Loring P, Cummins R, O'Grady A, et al. HER2 positivity in breast carcinoma: a comparison of ehromogenie in situ hybridization with fluorescence in situ hybridization in tissue mieroarrays, with targeted evaluation of intratumoral heterogeneity by in situ hybridization[J]. Appl Imruunohistochem Mol Morphol, 2005, 13:194-2130.
